I am the director of the Psychopharmacology and Emotional Research Lab (PERL) based at the University Department of Psychiatry in Oxford. We are a multi-disciplinary team including cognitive neuroscientists, psychiatrists, psychopharmacologists and psychologists.
We focus on the psychological mechanisms of antidepressant drug action with conventional and novel candidate treatments, challenging the typical division between these different approaches. To do this, we apply an experimental medicine approach, focused on neurocognitive measures of emotional processing in both healthy volunteers and patient samples.
This research helps to integrate psychological and pharmacological views of depression and treatment and has challenged the way in which we typically consider drug treatment for depression to work (see Harmer et al 2017). In addition this research has led to the development of human experimental models to explore the effects of novel drugs for the treatment of depression and anxiety. This work has also been applied in the clinic to provide an earlier marker of SSRI non-response in primary care (Browning et al., 2021).
Executive Committee Officer, European College of Neuropsychopharmacology (ECNP)
Council, British Neuroscience Association (BNA)
NIHR panel Research and Innovation for Global Health Transformation panel member
Wellcome Trust Expert Review Panellist (2016-2019)
Associate Editor for Psychological Medicine
Editorial board membership Biological Psychiatry and Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
DPhil, MA, DipLATHE
Associate Head of Department (People and Culture), Professor of Cognitive Neuroscience
- Research Fellow at Corpus Christi College
Read our Mental Elf blog on SSRIs and Psychotherapy for adolescent depression
Follow us on twitter @OxfordPERL
Experimental Medicine Hub
We have launched our NIHR BRC experimental medicine hub linking academia and industry to facilitate the use of experimental medicine approaches for treatment development - Experimental Medicine Industry Partnership (EMIP). See our AIM day blogs for our launch event
Cognitive Remediation in Bipolar (CRiB2): study protocol for a randomised controlled trial assessing efficacy and mechanisms of cognitive remediation therapy compared to treatment as usual
Tsapekos D. et al, (2023), BMC Psychiatry, 23
Real-world outcomes of concomitant antidepressant and statin use in primary care patients with depression: a population-based cohort study.
De Giorgi R. et al, (2023), BMC Med, 21
The long-term effects of ABM on symptom severity in patients with recurrent depression: A randomized sham-controlled trial.
Bø R. et al, (2023), J Affect Disord, 340, 886 - 892
Ultradian hydrocortisone replacement alters neuronal processing, emotional ambiguity, affect and fatigue in adrenal insufficiency: The PULSES trial.
Russell G. et al, (2023), J Intern Med
Cognitive predictors of stress-induced mood malleability in depression.
Bø R. et al, (2023), Anxiety Stress Coping, 1 - 15
Examining attentional functioning in depression using a personalized network approach: A proof-of-principle study
Kraft B. et al, (2023), Psychiatry Research Communications, 3
Combining antidepressants and attention bias modification in primary health care (DEPTREAT): Protocol for a pragmatic randomized controlled trial.
Landrø NI. et al, (2023), Contemp Clin Trials, 133
Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy.
Perini F. et al, (2023), Schizophrenia (Heidelb), 9
The pharmacological bases for repurposing statins in depression: a review of mechanistic studies.
De Giorgi R. et al, (2023), Transl Psychiatry, 13